Robert Cyran, U.S. tech columnist, joined Breakingviews in London in 2003 and moved four years later to New York, where he continues to cover global technology, pharmaceuticals and special situations. Robert began his career at Forbes magazine, where he assisted in the startup of the international version of the magazine. Before working at Breakingviews he worked as a market researcher and reporter covering the pharmaceutical industry. Robert has a Masters degree in economics from Birmingham University and an undergraduate degree from George Washington University. Follow Rob on Twitter @rob_cyran
- Tel: +1 646 223 6083
- E-mail: firstname.lastname@example.org
The U.S. top court decision upholding medical-coverage subsidies signals the official start of a race to consolidate. Centene and Health Net’s $6.3 bln deal gives the insurers an early lead. Big rivals like Cigna may catch up as the industry accepts that reform is here to stay.
Founder Phil Knight’s transfer of stock that allows him to elect a majority of the board to a foundation constitutes a foul of sorts. Though investors will give the sneaker giant a pass for its extraordinary performance, their successors may rue that failed call.
Celgene is paying a 100 pct premium for a 10 pct slice of two-and-a-half year-old Juno Therapeutics. That sounds bonkers, even for a fast-moving technology like immune cell modification. The sector is on a streak, but the risk of crapping out in drug development remains high.
- SpaceX flameout hardly heralds failure
- IAC investors may get a Match from partial divorce
- Palantir's mystery inflates its $20 bln valuation
- Anthem can afford to raise its premium for Cigna
- PayPal's post-partum future will eclipse eBay's
- Fat Americans inflate peculiar stock market bubble
- Under Armour dresses in ugly Google governance